No, Tcelna and the treatment being developed by Northwestern are two different approaches. The goal with Tcelna is to use it as a T-cell vaccine to try to get the body to get rid of rouge T-cells which are autoreactive against myelin. However, the goal with the Northwestern treatment is to induce immune tolerance of myelin autoantigens by either using dead T-cells loaded with myelin peptides or by using nanoparticles with attached myelin peptides.RyanYum wrote:so what does this mean, there is no drug out there that's gunna be as effective as they claimed this was supposed to be? Is this the same treatment that is posted here http://www.northwestern.edu/newscenter/ ... m_campaign
I'm just guessing on these time estimates, so take them with a large chunk of salt...RyanYum wrote:thx for clearing that up, how long before you think we see these treatments becoming a reality?
Since the Northwestern treatment study was phase I it still has to go through phase II and III. This could take 5-6 years or so if all goes well.
Tcelna is in phase IIb for SPMS. Its phase IIb for RRMS failed. We've been discussing Tcelna/Tovaxin for almost 9 years now. Assuming phase IIb with SPMS is successful (a big assumption), then it will still have to go through phase III. That could take a few years.